FDA approves Synribo for chronic myelogenous leukemia

The U.S. Food and Drug Administration recently approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML). Synribo is intended to be used in patients whose cancer progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors (TKIs), also used to treat CML.

Synribo is the second drug approved to treat CML in the past two months. On Sept. 4, 2012, the FDA approved Bosulif (bosutinib) to treat patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies.

More information: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm325895.htm